Kymera Therapeutics (KYMR) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 74.6% versus a gain of 6.2%. Over five years, KYMR leads with a +114.4% price change compared with +73.1% for NBIX. Neurocrine Biosciences is the larger company by market cap ($15.24 billion vs $9.84 billion), about 1.5 times the size.
Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | NBIX |
|---|---|---|
| Share price | $115.31 | $150.57 |
| Market cap | $9.84B | $15.24B |
| 1-day change | -3.42% | -3.84% |
| YTD return | +48.19% | +6.16% |
| 1-year return | +74.61% | +6.16% |
| 5-year return | +114.37% | +73.11% |
| P/E ratio (TTM) | — | 22.34 |
| Forward P/E | — | 12.24 |
| EPS (TTM) | $-3.64 | $6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.21M | $2.86B |
| Revenue growth (YoY) | -16.70% | +21.45% |
| Net income (latest FY) | $-311.35M | $478.60M |
| Gross margin | 0.00% | 98.18% |
| Operating margin | -891.07% | 21.64% |
| Net margin | -794.04% | 16.73% |
| 52-week high | $142.92 | $186.12 |
| 52-week low | $63.69 | $122.14 |
| Distance from 52-week high | -19.32% | -19.10% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +25.94% | +38.50% |
| Average volume | 852.46K | 1.34M |
| Shares outstanding | 85.37M | 101.22M |
| Employees | 285 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed NBIX by 68.4 percentage points over the past year.
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs -16.70%).
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
KYMR vs NBIX FAQ
Which is bigger, Kymera Therapeutics or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $15.24B compared with $9.84B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or NBIX?
KYMR returned +74.61% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are Kymera Therapeutics and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.